UN
Uday Nassa
About Uday Nassa
Data last updated:
Uday Nassa has 16 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Vindeca Life Sciences Private Limited and Fuelfour Therapeutics Llp. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Vindeca Life Sciences Private Limited at ₹7.27 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 07 Jul 2010 | 2010 | ₹7.27 Cr (FY 2025) | Active | |
| Designated Partner | 11 Oct 2024 | 2024 | – | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Uday Nassa
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Uday Nassa
Uday Nassa has 16 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Vindeca Life Sciences Private Limited and Fuelfour Therapeutics Llp. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Vindeca Life Sciences Private Limited at ₹7.27 Cr (FY 2025).
Uday Nassa is associated with 2 companies as Director and Designated Partner, including Vindeca Life Sciences Private Limited (₹7.27 Cr), Fuelfour Therapeutics Llp.
Uday Nassa has expertise in General Business.
Uday Nassa has 16 years in corporate governance.
By reported revenue, the largest current company of Uday Nassa is Vindeca Life Sciences Private Limited, with revenue of ₹7.27 Cr (FY 2025).
Uday Nassa currently holds positions at 2 companies: Vindeca Life Sciences Private Limited (₹7.27 Cr), Fuelfour Therapeutics Llp.